The plaintiffs must submit expert reports by November 18, 2024, unless they file for an extension
dose reduction of these medications may be needed) [1] Acute kidney injury risk, particularly with severe gastrointestinal adverse reactions causing dehydration Diabetic retinopathy complications , particularly in patients with a history of retinopathy who experience rapid improvement in blood glucose [1] Acute gallbladder disease including cholelithiasis and cholecystitis The FDA label includes a boxed warning about thyroid C-cell tumors observed in rodent studies, though the relevance to humans remains uncertain
Follow any specific instructions provided by the healthcare provider.
Int J Clin Pract 70(8):649656 Yaribeygi H, Farrokhi FR, Abdalla MA, Sathyapalan T, Banach M, Jamialahmadi T, et al (2021) The effects of glucagon-like peptide-1 receptor agonists and dipeptydilpeptidase-4 inhibitors on blood pressure and cardiovascular complications in diabetes
Understanding weight gain at menopause
When individuals on these medications view images of alcoholic beverages or alcohol-related scenarios, their brains show less activation in areas associated with craving and motivation than placebo-treated controls